About Pyxis Diagnostics
The human immune system can efficiently eradicate even widespread metastatic tumors, delivering durable survival benefit to cancer patients. Unfortunately, only a small subset of cancer patients benefit from immunotherapy; the rest lose valuable time and may suffer from diverse adverse events. Hence, biomarkers that predict a patient’s response to immunotherapy are in urgent need.
Immune Related Parameters
Over the years, several parameters were found to correlate with response to immunotherapy. The most prominent immune-related parameters are:
-
The various immune subsets’ relative abundance within the tumor
-
The expression and co-expression patterns of different Immune Check Point (ICP)-related molecules on each cell-subset
-
The immune state of each subset (e.g., activated, exhausted, its cytokine-polarization, metabolic state etc.)
Our Diagnostic Platform
Our diagnostic platform integrates all prominent immune parameters defined above and more, generating unique delineation of the tumor - immune - stroma microenvironment formed within human tumors.
This approach may provide better understanding on the structure and function of the inter-cellular communication network (ICCN) that protect tumor tissue from immune-mediated assault
Pyxis Mission
PyxisDX Develops a diagnostics platform for predicting IO drug response, and for the discovery of new drug combinations, by mapping the tumor-immune communication network.
Leading Team
Dr. Ari Tadmor, Ph.D.
CEO
Leading executive with a vast experience as a CEO of medical device and biotech start-up companies. Dr. Tadmor is proficient in fundraising, development of products all the way from idea to meeting the market.
Dr. Yosef Reut, Ph.D.
Chief Technology Officer
Vast industrial experience in multidisciplinary research and development of novel drugs in immuno-oncology, autoimmunity, ageing and development of computational platforms for precision medicine.
Yael Silberberg, Ph.D.
VP, Data Sciences
Experienced Data scientist, Computational Biologist and software engineer, with years of management experience in multidisciplinary research and development.
Dr. Ilan Volovitz, Ph.D.
Chief Scientific Officer
Head of Cancer Immunotherapy lab.
The Neurosurgery department,
Tel-Aviv Sourasky Medical Center
Dr. Ravit Geva, M.D.
Chief Medical Officer
Head of the GIT malignancies center. Head of the oncology clinical research & Innovation unit, Deputy director of the oncology division at the medical center in Tel Aviv Sourasky Medical Center, Israel.
Avia Zisso, M.Sc., M.D.
R&D Scientist
Multidisciplinary combination of molecular genetics tools and bioinformatic analysis: library preparation, sequencing and analysis, decoding of DNA sequences for clinical diagnosis using various high throughput bioinformatic tools.
Board
Ori Choshen
Chairman of the Board
Ori is a multi-disciplinary Biotech, Computational Biology and AI investor and company builder with passion for innovation, venture creation, BD and bringing novel drugs and treatments to market.
Ori is leading VLX Ventures for the last 8 years, after a 12 years’ career in the Hi-Tech industry.
Anat Cohen-Dayag, Ph.D
Board, President and CEO of Compugen
Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms
Scientific Advisory Board
Dr. David Perry
Scientific advisory Board member
Dr. Perry served for approximately 25 years in R&D execu- tive roles in both large and small companies. Dr. Perry held position in companies such as Novo Nordisk (Copenhagen), Roche (Palo Alto), Cephalon (London), and Ferring (Copen- hagen). Most recently David served as Baxter Bioscience’s global head of clinical and medical affairs, leading their clini- cal development efforts across all therapy areas.
Raanan Berger, M.D, Ph.D
Clinical Advisor
Dr. Berger is the Director of the Sheba Cancer Center, a senior Oncologist and Radiotherapist, heading the clinical research facility in the Institute of Oncology and Radiotherapy at the Sheba Medical Center. Prof. Berger is leading the genitourinary oncology program, as well as running a basic and translational research lab.
Prof. Igor Ulitsky, Associate Professor at Weizmann Institute of Science, Advisory
Dr. Igor Ulitsky studies the biology of long non-coding RNA (lncRNA) and their functions in regulatory networks controlling gene expression.
Igor is an expert in RNA-sequencing data analysis.
Collaborations
